Fundraising FoxMonograph Capital Partners — 2025 Investments
3 investments dated 2025 · listed companies and verified rows first · show all
Elevara Medicines is a clinical-stage biotech developing ELV001, a first-in-class once-daily oral CDK4/6 inhibitor that targets fibroblast-like synoviocytes as an add-on therapy for rheumatoid arthritis and other chronic inflammatory diseases.
BiotechHealthtechMedical DevicesLondon, GB
Emma Tinsley(Founder & former CEO (now Non-Executive Director))inMai-Britt Zocca(CEO)in
Co-investorsSofinnova PartnersForbion
Nocion Therapeutics develops small molecule charged sodium channel blockers (nocions) designed to silence overactive sensory nerves.
BiotechHealthtechMedical DevicesWatertown, US
MATTHEW FRANKEL(Executive Officer)inPETER COUROSSI(Executive Officer)RICHARD BATYCKY(President and Chief Executive Officer)JAMES ELLIS(Executive Officer)MICHAEL LIPP(Executive Officer)inCHRISTOPHER SILBER(Executive Officer)in
Board seatFreddie Dear· per SEC Form D
Co-investorsCanaan PartnersF-Prime CapitalLumira VenturesMission BiocapitalOUP (Osage University Partners)
Ouro Medicines is a biotechnology company developing cell-depleting therapies aimed at resetting the immune system to treat chronic immune-mediated diseases such as autoimmune and autoinflammatory conditions.
BiotechHealthtechSouth San Francisco, US
Jaideep(Founding Chief Executive Officer)Neely Mozaffarian(Chief Medical Officer)inChristina(General Counsel & Chief Operating Officer)
Co-investorsNew Enterprise Associates (NEA)Norwest Venture PartnersTPG
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.